Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)
Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidateThe company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concernsTryp is preparing Phase 2a and Phase 2b clinical trials…